Q2 2026展望报告

May 2026 Table ofContents AbouttheAuthor.................................................................................................................................3ExecutiveSummary............................................................................................................................3Disclaimer...........................................................................................................................................3Data Analysis………………………………………………………………………………………………….4Drugs.................................................................................................................................................7Regulatory Approvals..................................................................................................................................7OclaizforAcromegaly..................................................................................................................................................7CTx-1301 for Attention Deficit Hyperactivity Disorder (ADHD)....................................................................................8Nilopki for Chronic Myelogenous Leukemia (CML)......................................................................................................9Xocova for COVID-19 Prevention..............................................................................................................................10vepdegestrant for HR+/HER2-Breast Cancer...........................................................................................................11baxdrostatforHypertension (Systemic).....................................................................................................................12Sonrotoclax for Mantle Cell Lymphoma–NHL..........................................................................................................13Ranluspec for Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology)..............................................14Zoryve for Psoriasis....................................................................................................................................................15BAT-2506 for Rheumatoid Arthritis (RA)....................................................................................................................16veligrotug for Thyroid Eye Disease (TED)..................................................................................................................17Datroway for Triple-Negative Breast Cancer (TNBC)................................................................................................18Data Readouts..........................................................................................................................................19OCS-01 for Diabetic Macular Edema (Ophthalmology).............................................................................................19Venglustat for Fabry's Disease...................................................................................................................................20d-Lysergic acid diethylamide bitartrate for Generalized Anxiety Disorder (GAD)......................................................21Xervyteg for Melanoma..............................................................................................................................................22efruxifermin for Non-AlcoholicSteatohepatitis (NASH)..............................................................................................23Survodutide for Obesity..............................................................................................................................................24Ralinepag for Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension (PH)......................................25Deals................................................................................................................................................26Gyre Therapeutics Acquisition of Cullgen Completed...................................................................................................26Gilead Sciences Acquisition of Arcellx Completed........................................................................................................26Gilead Sciences Acquisition of Tubulis Completed.......................................................................................................27Eli Lilly Acquisition Orna Therapeutics Completed........................................................................................................27Eli Lilly Acquisition of Ventyx Biosciences Completed...................................................................................................28Merck Acquisition of Terns Pharmaceuticals Completed...............................................................................................28 AbouttheAuthor Biomedtrackeris anindependent research service that offers proprietary clinica